1. Дамулин И.В., Парфенов В.А., Скоромец А.А., Яхно Н.Н. Нарушения кровообращения в головном и спинном мозге. В кн.: Болезни нервной системы. Руководство для врачей. Под ред. Н.Н.Яхно, Д.Р.Штульмана. Т. 1. М.: Медицина, 2001; с. 231–302.
2. Pasquier F, Leys D. Why are stroke patients prone to develop dementia? J Neurol 1997; 244; 135–42.
3. Inzitari D, Di Carlo A, Pracucci G et al. Incidence and determinants of poststroke dementia as defined by an informant interview method in a hospital-based stroke registry. Stroke1998; 29 (10): 2087–93.
4. Pohjasvaara T, Erkinjuntti T, Ylikoski R et al. Clinical determinants of poststroke dementia. Stroke 1998; 29: 75–81.
5. Barba R, Martínez-Espinosa S, Rodríguez-García E et al. Poststroke dementia. Clinical features and risk factors. Stroke 2000; 31: 1494-501.
6. Leys D, Henon H, Pasquier F. The role of cerebral infarcts in vascular dementia. In: Research and Practice in Alzheimer’s Disease. B.Vellas et al (eds.). Paris: Serdi Publisher, 2001; 5: 123–8.
7. Tatemichi TK, Foulkes MA, Mohr JP et al. Dementia in stroke survivors in the Stroke Data Bank cohort: Prevalence, incidence, risk factors, and computed tomographic findings. Stroke 1990; 21 (6): 858–66.
8. Верещагин Н.В., Калашникова Л.А., Гулевская Т.С., Миловидов Ю.К. Болезнь Бинсвангера и проблема сосудистой деменции. Журн. невролог. и психиатр. 1995; 95 (1): 98–103.
9. Дамулин И.В. Сосудистая деменция. Невролог. журн. 1999; 4 (3): 4–11.
10. Дамулин И.В. Болезнь Альцгеймера и сосудистая деменция. Под ред. Н.Н.Яхно. М., 2002.
11. Cummings JL. Vascular subcortical dementias: Clinical aspects. In: Vascular Dementia. Etiological, Pathogenetic, Clinical and Treatment Aspects. Ed by L.A.Carlson, C.G.Gottfries, B.Winblad. Basel etc: S.Karger, 1994; p. 49–52.
12. Gorelick PB. Status of risk factors for dementia associated with stroke. Stroke 1997; 28: 459–63.
13. Winblad B, Fioravanti M, Dolezal T et al. Therapeutic use of nicergoline. Clin Drug Invest 2008; 28: 533–52.
14. Winblad B, Carfagna N, Bonura L et al. Nicergoline in dementia. A review of its pharmacological properties and therapeutic potential. CNS Drugs 2000: 14: 267–87.
15. Nappi G, Bono G, Merlo G et al. Long-term nicergoline treatment of mild to moderate senile dementia. Results of a multicentre, double-blind, placebo-controlled study. Clin Drug Invest 1997; 13: 308–16.
16. Bes A, Orgogozo J-M, Poncet M et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol 1999; 6: 313–22.
Авторы
И.В.Дамулин
Кафедра нервных болезней ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ